{"id":"human-bcma-targeted-t-cells-injection","safety":{"commonSideEffects":[{"rate":"null","effect":"Cytokine release syndrome"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BCMA-targeted T cells are a type of immunotherapy that targets the B-cell maturation antigen (BCMA) on the surface of cancer cells.","oneSentence":"BCMA-targeted T cells","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:00:09.756Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT07234773","phase":"PHASE1","title":"A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA).","status":"RECRUITING","sponsor":"Kali Therapeutics, Inc.","startDate":"2026-03-06","conditions":"Rheumatoid Arthritis (RA)","enrollment":24},{"nctId":"NCT07185490","phase":"EARLY_PHASE1","title":"IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-02-15","conditions":"Relapsed/Refractory Multiple Myeloma (RRMM), Plasma Cell Leukemia (PCL)","enrollment":40},{"nctId":"NCT07055724","phase":"PHASE2","title":"Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis","status":"NOT_YET_RECRUITING","sponsor":"Nanjing IASO Biotechnology Co., Ltd.","startDate":"2025-07","conditions":"AL Amyloidosis","enrollment":17},{"nctId":"NCT06655519","phase":"PHASE1","title":"An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-10-25","conditions":"Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia","enrollment":12},{"nctId":"NCT05698303","phase":"PHASE1","title":"A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"Nanjing IASO Biotechnology Co., Ltd.","startDate":"2023-05-08","conditions":"Multiple Myeloma","enrollment":12},{"nctId":"NCT05594797","phase":"PHASE2","title":"Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM","status":"RECRUITING","sponsor":"Hrain Biotechnology Co., Ltd.","startDate":"2022-07-12","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT05181501","phase":"PHASE1","title":"A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)","status":"NOT_YET_RECRUITING","sponsor":"Nanjing IASO Biotechnology Co., Ltd.","startDate":"2022-04","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT05066646","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)","status":"UNKNOWN","sponsor":"Nanjing IASO Biotechnology Co., Ltd.","startDate":"2020-04-01","conditions":"Multiple Myeloma","enrollment":132},{"nctId":"NCT04003168","phase":"PHASE1","title":"Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"Hrain Biotechnology Co., Ltd.","startDate":"2019-07-01","conditions":"Multiple Myeloma","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BCMA CAR-T"],"phase":"phase_2","status":"active","brandName":"Human BCMA Targeted T Cells Injection","genericName":"Human BCMA Targeted T Cells Injection","companyName":"Hrain Biotechnology Co., Ltd.","companyId":"hrain-biotechnology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BCMA-targeted T cells Used for Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}